Wird geladen...
Systemic treatment of non-small cell lung cancer brain metastases
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib o...
Gespeichert in:
| Veröffentlicht in: | Contemp Oncol (Pozn) |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Termedia Publishing House
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5371701/ https://ncbi.nlm.nih.gov/pubmed/28373815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2016.64593 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|